前列腺特异性抗原测试和前列腺癌相关的结果:丹麦全国性的研究
Frederik K Palshof1,2, Lina S Mørch1, Klaus Brasso3,4
1Cancer and Medicine, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
BJU international
|March 5, 2026
概括
在丹麦,前列腺特异性抗原 (PSA) 检测仍然很高,特别是在老年男性中,尽管指南建议对无症状个体进行检测. 这种PSA检测的高普及率要求重新评估其可访问性,以减轻不必要的程序可能造成的危害.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 公共卫生 公共卫生
- 在瘤学瘤学.
背景情况:
- 丹麦的国家指南和从业人员培训建议不对无症状男性进行前列腺特异抗原 (PSA) 测试.
- 尽管有建议,但在公共资助的医疗保健系统中,PSA测试的实际使用和结果需要评估.
研究的目的:
- 评估丹麦国家医疗保健系统中PSA检测率和相关的前列腺癌结局.
- 为讨论PSA测试的可用性和必要性提供信息,考虑潜在的危害.
主要方法:
- 通过使用健康登记数据,分析了1920年至1970年间出生的丹麦男性的全国队列.
- 根据年龄标准化的比率和100岁的累积发病率计算PSA检测,前列腺组织学,活检,前列腺癌诊断和前列腺癌特定死亡.
- 用Aalen Johansen估计器与延迟输入来进行估计.
主要成果:
- 观察到PSA检测的高率,年龄标准化率为2023年每10万男性14659人,70-79岁的男性达到峰值.
- 100年后的累积发病率显示PSA检测为84%,前列腺癌诊断为12%,前列腺癌特定死亡为5.0%.
- 初始PSA测试时的平均年龄为60岁,诊断时为72岁,死亡时为84岁.
结论:
- 与现有的指导方针相反,PSA检测率很高,在丹麦老年男性中很常见.
- 这些发现表明需要重新考虑PSA测试的可访问性,以尽量减少过度诊断和过度治疗的危害.
- 这项研究支持关于广泛PSA查的益处与风险的持续辩论.
相关概念视频
01:20Disorders of the Male Reproductive System
5.3K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.3K
01:21Cancer Survival Analysis
806
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
806